System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gian Luca Forni is an expert in Hematology at Istituto Giannina Gaslini (Italy). As of September 2026, ScienceLeadR ranks Gian Luca Forni in the top 1% of experts worldwide for Anemia. Gian Luca Forni has authored 259 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 1 of them ongoing. SLR score: 956 (community average: 125). How the SLR is computed.

LeadR Profile

Gian Luca Forni Istituto Giannina Gaslini Italy
956 ScienceLeadR Reputation 956

Unlock

Register Login
Network Map

Hematology

Subspecialties: Genetics - Public Health - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Istituto Giannina Gaslini

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 259

Citations

Citations: 8 435 1st author: 19 Last author: 70 Unique author: 0

Main journals

Blood 53
Am J Hematol 25
Haematologica 19
Hemasphere 14
Br J Haematol 10

Best Journals

N Engl J Med 4
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Colchicine Protects Against Sickle Cell Related Cardiomyopathy: Evidence of the Novel Role of Inflammaging.
PMID 42650176 — cells, growth, colchicine, anemia, sickle cell, heart, inflammasomes, therapeutics, cardiomyopathies		Antioxidants (Basel)20260
Update of the decision-making algorithm on selecting transfusion-dependent β-thalassemic patients for gene therapy approaches: joint consensus report on behalf of EHA-specialized working group and EBMT hemoglobinopathies working party.
PMID 42463828 — cells, genes, decision making, algorithms, thalassemia, therapeutics, hemoglobinopathies		Bone Marrow Transplant20260
The Emerging Role of Liver Stiffness Measurement in Transfusion Dependent Thalassemia.
PMID 42015303 — research design, hematology, fibrosis, liver, thalassemia, liver stiffness		Am J Hematol20260
Refined classification and phenotype-driven analysis of PIEZO1 variants in hereditary red cell and iron disorders.
PMID 42013021 — cells, hematology, phenotype, classification, iron overload, genotype		Blood20260
Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patients.
PMID 41844555 — thromboembolism, hematology, safety		Br J Haematol20260

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 7
Phase 2 5
Phase 3 4
Phase 1 1

By status:

Completed 13
Terminated 2
Active not recruiting 1
Recruiting 1

By type:

Interventional 11
Observational 6

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 3
multicentricup10 8

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non Transfusion Dependent Alpha or Beta Thalassemia ( or NTDT)
NCT04770753 — safety, beta-thalassemia, alpha-thalassemia, tablets, thalassemia		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS